New Treatments in the Pipeline for Pemphigus

The lecture discusses advancements in treatments for pemphigus, a severe blistering disease, focusing on treatment assessment, existing approved therapies, and ongoing clinical trials. The speaker highlights the challenges in managing this condition, particularly the reliance on high doses of corticosteroids, which can lead to considerable side effects and complications. Recent trials have found that rituximab significantly improves treatment outcomes compared to traditional steroid therapies, with lower relapse rates and fewer side effects. However, there's still a need for more effective treatments with fewer long-term consequences, especially considering risks associated with immunosuppression during the COVID-19 pandemic. New therapies under investigation include Bruton tyrosine kinase inhibitors, such as rosabrutinib, and FCRN inhibitors, which show promise for achieving better disease control with lower steroid use. Other novel approaches in clinical trials include CAR T-cell therapy and fast ligand inhibitors. The discussion underscores the importance of validated outcome measures in the development of new treatments to address unmet needs in pemphigus management. Collaboration among researchers, organizations like the Pemphigus Foundation, and regulatory agencies is essential for enhancing patient care and accelerating the approval of safer, more effective therapeutics.